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Abstract— Aim: Pathological gambling and comorbid alcohol dependence often occur in combination. Disulﬁram is one of the
proven drugs for alcohol dependence. In addition to its inhibiting acetaldehyde dehydrogenase, disulﬁram inhibits dopamine β-
hydroxylase and may thereby increase dopamine and decrease norepinephrine cerebral concentrations. Because there may be
common neurochemical substrates and neuronal circuits for pathological gambling and addiction, we wished to explore the eﬀect
of disulﬁram in gambling. Method: We describe the outcome of a patient with alcohol dependence and pathological gambling
treated with disulﬁram D. Results: During treatment with disulﬁram, the patient reported that his desire to gamble disappeared
entirely. Follow-up indicated that he has not gambled for >12 months. Conclusions: Although uncontrolled case observations
should be interpreted with caution, disulﬁram deserves further investigation in pathological gambling.
INTRODUCTION
Pathological gambling (PG) is a public health problem char-
acterized by recurrent and pathological patterns of gambling.
PG is associated with a range of social and psychological pro-
blems like high rates of bankruptcy, divorce, suicide and
reduced quality of life. Although the lifetime prevalence rate
of pathological gambling in the German population is 0.2–
0.4%, it often remains unrecognized and, therefore, untreated
(Wölﬂing et al., 2009). Comorbidity of DSM-IV pathological
gambling and other psychiatric disorders are very common. In
particular, high comorbidity rates have been reported between
PG and drug dependence. Rates vary from 34 to 80% for sub-
stance use disorders (excluding tobacco) (Hall et al., 2000;
McCormick et al., 1984). The occurrence of PG in alcohol-
dependent patients is at least three times higher than in the
general population (Hall et al., 2000). In cocaine-dependent
patients, lifetime comorbidity rates have been reported that
are even ﬁve times higher as in the general population (Hall
et al., 2000). These observations suggest that common patho-
physiological factors might underlie PG and drug addiction.
However, this hypothesis is not proven yet.
PG is currently classiﬁed as an ‘impulse control disorder
(ICD) not elsewhere categorized’ in the DSM, although the
current diagnostic criteria indeed share many features with
those for drug dependence, including (i) continued engage-
ment in a behaviour despite adverse consequences, (ii)
diminished self-control over engagement in the behaviour,
(iii) compulsive engagement in the behaviour and (iv) an ap-
petitive urge or craving state prior to engaging in the
behaviour as well as tolerance and withdrawal (Potenza,
2006, 2008). Similarities between PG and drug dependence
include not only phenomenological criteria but also epidemi-
ological, clinical, genetic and neurobiological characteristics
(Goudriaan et al., 2004; Potenza, 2006, 2008). Therefore,
PG might best be characterized as a non-substance-related
or behavioural addiction with a compulsive urge for a non-
drug reward (Tamminga and Nestler, 2006).
Recent evidence indicates that similar mechanisms are in-
volved in PG and drug addiction. Neuroimaging data suggest
that in PG and drug addiction, the same brain areas are in-
volved. Reduced activity in the ventral striatum and the
ventromedial and ventrolateral prefrontal cortex has been re-
ported in PG, which is also a hallmark of drug addiction
(Reuter et al., 2005). A neuroendocrinological study in casino
gamblers found that gambling elevated dopamine levels in
problem gamblers more than in healthy controls (Meyer et
al., 2004). The mesocorticolimbic dopaminergic system has
been found to be implicated in rewarding and reinforcing be-
haviours. It has been suggested that PG might be related to a
deﬁciency of the mesocorticolimbic dopaminergic reward sys-
tem, as has been shown for drug addiction.
Another hallmark of drug addiction that also holds for path-
ological gambling is the inability to inhibit inappropriate
responses. Accumulating evidence points towards an impor-
tant role of brain dopamine and noradrenergic systems in
impulsive behaviour. The inferior frontal gyrus is critically in-
volved in response inhibition and might be particularly
impacted by the brain’s noradrenergic system.
Other preclinical studies suggest that engaging in casinogam-
bling elevates activity of the hypothalamic–pituitary axis in
problem and non-problem gamblers, as indicated by increased
plasma levels of norepinephrine, cortisol and increased heart
rate. Roy and colleagues found higher levels of norepineph-
rine or its metabolites in urine, blood or cerebrospinal ﬂuid
samples in pathologic gamblers (Roy et al., 1988).
The similarities between PG and drug addiction suggest
that patients with pathological gambling may also beneﬁt
from medication used for the treatment of drug addiction.
Pharmacotherapy research and validated treatment options
for PG are limited.. At the present time, there is no medication
for treatment of PG that is approved by the Food and Drug
Administration. Controlled clinical trials provide some evi-
dence for beneﬁcial eﬀects of opiate antagonists (naltrexone
and nalmefene) (Grant et al., 2006; Kim et al., 2001), N-
acetyl-cysteine (Grant et al., 2007), lithium (Hollander et al.,
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2005) and selective serotonin reuptake inhibitors, which have
been shown to reduce craving for gambling. Additionally, cog-
nitive behavioural therapy has been shown to be an eﬀective
treatment for some patients with PG. However, all these thera-
pies have only limited success.
Disulﬁram is well known as a treatment for alcohol depen-
dence (e.g. de Sousa and de Sousa 2004, 2005; Suh et al.,
2006; Laaksonen et al., 2009). Disulﬁram also helps in the
treatment of cocaine addiction (Carroll et al., 2004; Gossop
and Carroll, 2006), possibly by reducing cocaine craving by
increasing neurotransmitter levels of dopamine and decreasing
the norepinephrine levels by blocking the activity of the en-
zyme dopamine beta hydroxylase (DBH) involved in the
metabolism of brain monoamines (Weinshenker and Schroe-
der, 2007; Mutschler et al., 2009a, 2009b). As similar
neurochemical disturbances have been reported in PG, disul-
ﬁram might not only be eﬀective in the treatment of cocaine
addiction but also in the treatment of PG (Mutschler et al.,
2009a, 2009b).
We present a case in which a patient with PG and comorbid
alcohol dependence was treated with disulﬁram. We suggest
that disulﬁram has the potential to reduce craving and patho-
logical gambling behaviour in PG.
CASE REPORT
Mr K. is a 48-year-old married male working as a part-time
nurse. His alcohol dependence developed 25 years ago. He
also started problematic gambling at slot machines at around
the same time. He met all of the criteria for PG according to
DSM-IV and ICD-10 for ∼20 years. The patient has no crim-
inal history, but has run up about 10,000 euros in debts due to
PG. Mr K is a smoker and nicotine-addicted but has never tak-
en any illegal drugs.
He was treated for alcohol dependence for the ﬁrst time
∼10 years ago. He has undergone 28 inpatient detoxiﬁcations.
In 2000, he had long-term residential treatment for alcohol de-
pendence. Afterwards, he participated in a self-help group on
a regular basis but did not receive speciﬁc treatment for PG.
He remained completely abstinent from alcohol for 6–7
months. However, he continued to gamble during those alco-
hol-abstinent months.
After the ﬁrst contact with our team in 2008, he was treated
for 5 weeks in our inpatient department, which specializes in
addiction medicine. The treatment included behavioural ther-
apy as well as relapse prevention medication with disulﬁram
(dosage 500 mg/3 days per week). The patient tolerated the
medication without any side eﬀects (apart from short-term,
moderate fatigue at the beginning of the treatment).
After discharge from our inpatient treatment, we continued
treating the patient over a period of 12 months in our outpa-
tient programme for chronic alcohol patients. The disulﬁram
medication was supervised by a physician three times per
week, establishing a therapeutic ritual with high frequency
of short-term individual contacts. During this therapeutic rit-
ual, the therapist praised the patient for taking disulﬁram and
for maintaining abstinence, thereby providing continuous rein-
forcement of an alcohol-free lifestyle. Additionally, alternative
coping skills were developed and breathalyzer tests to monitor
abstinence from alcohol were conducted. Throughout this
treatment, the patient reported that not only craving for alco-
hol had disappeared but that he surprisingly had no urge to
gamble anymore.
In conclusion, we found that, since initiating the supervised
treatment with disulﬁram, the patient has been abstinent from
alcohol and gambling for >12 months.
DISCUSSION
This case report suggests that disulﬁram might provide treat-
ment in PG. Disulﬁram helps in the treatment of alcoholism,
cocaine addiction, human cancers and fungal infections
(Brewer, 1990; Suh et al., 2006; Cvek and Dvorak, 2008).
For more than half a century, disulﬁram has been successfully
used for alcohol aversion therapy (Brewer, 1993). Disulﬁr-
am’s pharmacokinetics have been extensively studied; it
also has a good safety record (Suh et al., 2006). It is a well-
known vicious circle that substance use may lead to more
gambling and more gambling may lead to substance use. Per-
sonality traits like impulsivity and reward sensitivity may
contribute to excessive engagement in both behaviours.
In the presented case, the patient has abstained from alcohol
consumption for >12 months now and, notably, he has not
gambled either since treatment with disulﬁram started. One
possible explanation might be that the patient was abstinent
from alcohol. However, it can be argued that the patient
was treated for alcohol dependence several times, but PG
was never markedly aﬀected. Furthermore, despite numerous
previous detoxiﬁcations, the patient had never been treated
with supervised disulﬁram before.
Psychological aspects of the supervised disulﬁram therapy
and the high placebo response rate seen in treatment studies of
pathological gambling may have contributed to the good clin-
ical outcome, and this is a methodological limitation of this
case report.
However, we propose that a possible neurobiological con-
tributant might be that disulﬁram directly modulates reward
sensitivity and craving for gambling by increasing the level
of the brain chemical dopamine and decreasing the norepi-
nephrine levels through blocking the activity of the DBH,
which metabolizes brain monoamines (Mutschler et al.,
2009a, 2009b). Most strikingly, these two neurotransmitter
systems are thought to be altered in PG (Reuter et al., 2005;
Roy et al., 1988).
The disappearance of the patient’s desire to gamble during
treatment with disulﬁram points towards the potential of disul-
ﬁram in reward modulation in PG, similar to that described in
the treatment of cocaine dependence (Mutschler et al., 2009a,
2009b). Our preliminary clinical data support the hypothesis
that disulﬁram aﬀects the desire to gamble, thereby promoting
gambling abstinence. The possible involvement of DBH was
mentioned above.
Previous studies in drug-dependent patients and patients
with PG have shown that a combination of pharmacological
treatment in combination with psychosocial treatment meth-
ods, group therapies or contingency management therapies
is more eﬀective than either treatment alone (Oakley-Browne
et al., 2000; Pallesen et al., 2007). More studies investigating
the potential of combined treatment approaches using disulﬁ-
ram and cognitive behavioural therapies are necessary.
In summary, this report suggests that disulﬁram might be
a promising pharmacological agent in the treatment of PG.
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Future studies should assess the eﬃcacy of disulﬁram in redu-
cing relapse rates in larger samples of pathological gamblers
without comorbid alcohol dependence, with research to under-
stand the underlying neuronal mechanisms.
Acknowledgement—This work was supported by the Central Institute of Mental Health
Mannheim, Germany.
REFERENCES
Brewer C. (1990) Combining pharmacological antagonists and beha-
vioural psychotherapy in treating addictions. Why it is eﬀective
but unpopular. Br J Psychiatry 157:34–40.
Brewer C. (1993) Recent developments in disulﬁram treatment.
Alcohol Alcohol 28:383–95.
Carroll KM, Fenton LR, Ball A et al. (2004) Eﬃcacy of disulﬁram
and cognitive behavior therapy in cocaine-dependent outpatients:
a randomized placebo-controlled trial. Arch Gen Psychiatry
61:264–72.
Cvek B, Dvorak Z. (2008) The value of proteasome inhibition in can-
cer. Can the old drug, disulﬁram, have a bright new future as a
novel proteasome inhibitor? Drug Discov Today 13:716–22.
de Sousa A, de Sousa A. (2004) A one-year pragmatic trial of nal-
trexone vs disulﬁram in the treatment of alcohol dependence.
Alcohol Alcohol 6:528–31.
de Sousa A, de Sousa A. (2005) An open randomized study compar-
ing disulﬁram and acamprosate in the treatment of alcohol
dependence. Alcohol Alcohol 40:545–8.
Gossop M, Carroll KM. (2006) Disulﬁram, cocaine, and alcohol: two
outcomes for the price of one? Alcohol Alcohol 41:119–20.
Goudriaan AE, Oosterlaan J, De Beurs E et al. (2004) Pathological
gambling: a comprehensive review of biobehavioral ﬁndings.
Neurosci Biobehav Rev 28:123–41.
Grant JE, Kim SW, Odlaug BL. (2007) N-Acetyl cysteine, a
glutamate-modulating agent, in the treatment of pathological
gambling: a pilot study. Biol Psychiatry 62:652–7.
Grant JE, Potenza MN, Hollander E et al. (2006) Multicenter inves-
tigation of the opioid antagonist nalmefene in the treatment of
pathological gambling. Am J Psychiatry 163:303–12.
Hall GW, Carriero NJ, Takushi RY et al. (2000) Pathological gam-
bling among cocaine-dependent outpatients. Am J Psychiatry
157:1127–33.
Hollander E, Pallanti S, Allen A et al. (2005) Does sustained-release
lithium reduce impulsive gambling and aﬀective instability versus
placebo in pathological gamblers with bipolar spectrum disor-
ders? Am J Psychiatry 162:137–45.
Kim SW, Grant JE, Adson DE et al. (2001) Double-blind naltrexone
and placebo comparison study in the treatment of pathological
gambling. Biol Psychiatry 49:914–21.
Laaksonen E, Koski-Jannes A, Salaspuro M et al. (2009) A random-
ized, multicentre, open-label, comparative trial of disulﬁram,
naltrexone and acamprosate in the treatment of alcohol depen-
dence. Alcohol Alcohol 43:53–61.
McCormick RA, Russo AM, Ramirez LF et al. (1984) Aﬀective dis-
orders among pathological gamblers seeking treatment. Am J
Psychiatry 141:215–8.
Meyer G, Schwertfeger J, Exton MS et al. (2004) Neuroendocrine
response to casino gambling in problem gamblers. Psychoneur-
oendocrinology 29:1272–80.
Mutschler J, Bühler M, Diehl A et al. (2009a) Disulﬁram, an
old drug with new potential in the treatment of pathological
gambling? Med Hypotheses Electronic publication ahead of
print.
Mutschler J, Diehl A, Kiefer F. (2009b) Pronounced paranoia as a
result of cocaine–disulﬁram interaction: case report and mode
of action. J Clin Psychopharmacol 29:99–101.
Oakley-Browne MA, Adams P, Mobberley PM. (2000) Interven-
tions for pathological gambling. Cochrane Database Syst Rev
18:1521.
Pallesen S, Molde H, Arnestad HM et al. (2007) Outcome of phar-
macological treatments of pathological gambling: a review and
meta-analysis. J Clin Psychopharmacol 27:357–64.
Potenza MN. (2006) Should addictive disorders include non-
substance-related conditions? Addiction 101:1142–51.
Potenza MN. (2008) The neurobiology of pathological gambling and
drug addiction: an overview and new ﬁndings. Philos Trans R Soc
Lond B Biol Sci 363:3181–9.
Potenza MN, Kosten TR, Rounsaville BJ. (2001) Pathological gam-
bling. JAMA 286:141–4.
Reuter J, Raedler T, Rose M et al. (2005) Pathological gambling is
linked to reduced activation of the mesolimbic reward system.
Nat Neurosci 8:147–8.
Roy A, Adinoﬀ B, Roehrich L et al. (1988) Pathological gambling.
A psychobiological study. Arch Gen Psychiatry 45:369–73.
Suh JJ, Pettinati HM, Kampman K et al. (2006) The status of
disulﬁram: a half of a century later. J Clin Psychopharmacol
26:290–302.
Tamminga CA, Nestler EJ. (2006) Pathological gambling: focusing
on the addiction. Am J Psychiatry 163:180–1.
Weinshenker D, Schroeder JP. (2007) There and back again: a tale of
norepinephrine and drug addiction. Neuropsychopharmacology
32:1433–51.
Wölﬂing K, Bühler M, Lemenager T et al. (2009) Gambling and in-
ternet addiction: review and research agenda. Nervenarzt 80:
1030–9.
Mutschler et al.216
 at Universität Zürich. Hauptbibliothek Irchel on January 27, 2011
alcalc.oxfordjournals.org
D
ow
nloaded from
 
